Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert T Keenan

Showing results (1-10 of 45) with videos related to

Pageof 5
Sort By:
Seminars in Arthritis and Rheumatism|July 5, 2020
The biology of urateRobert T Keenan
Clinical Therapeutics|January 17, 2017
Limitations of the Current Standards of Care for Treating Gout and Crystal Deposition in the Primary Care Setting: A ReviewRobert T Keenan
The Journal of Rheumatology|July 3, 2019
Is It Time for Gout Flare Treatment to Move into the 21st Century?Robert T Keenan
Rheumatic Diseases Clinics of North America|November 10, 2012
Safety of urate-lowering therapies: managing the risks to gain the benefitsRobert T Keenan
Rheumatology and Therapy|March 4, 2019
Moving the Needle: Improving the Care of the Gout PatientJon Golenbiewski, Robert T Keenan
Current Rheumatology Reports|April 22, 2016
New and Pipeline Drugs for GoutRobert T Keenan, Naomi Schlesinger
Current Rheumatology Reports|April 29, 2010
Gout, hyperuricemia, and the risk of cardiovascular disease: cause and effect?Ankoor Shah, Robert T Keenan
Bulletin of the NYU Hospital for Joint Diseases|October 22, 2008
Update on the management of hyperuricemia and goutMichael H Pillinger, Robert T Keenan
Drugs of Today (Barcelona, Spain : 1998)|June 6, 2009
Febuxostat: a new agent for lowering serum urateRobert T Keenan, Michael H Pillinger
Current Rheumatology Reports|January 12, 2013
Genetics of hyperuricemia and gout: implications for the present and futureRonald L George, Robert T Keenan
Pageof 5

Showing results (1-10 of 45) with videos related to

Sort By:
Pageof 5
Seminars in Arthritis and Rheumatism|July 5, 2020
The biology of urateRobert T Keenan
Clinical Therapeutics|January 17, 2017
Limitations of the Current Standards of Care for Treating Gout and Crystal Deposition in the Primary Care Setting: A ReviewRobert T Keenan
The Journal of Rheumatology|July 3, 2019
Is It Time for Gout Flare Treatment to Move into the 21st Century?Robert T Keenan
Rheumatic Diseases Clinics of North America|November 10, 2012
Safety of urate-lowering therapies: managing the risks to gain the benefitsRobert T Keenan
Rheumatology and Therapy|March 4, 2019
Moving the Needle: Improving the Care of the Gout PatientJon Golenbiewski, Robert T Keenan
Current Rheumatology Reports|April 22, 2016
New and Pipeline Drugs for GoutRobert T Keenan, Naomi Schlesinger
Current Rheumatology Reports|April 29, 2010
Gout, hyperuricemia, and the risk of cardiovascular disease: cause and effect?Ankoor Shah, Robert T Keenan
Bulletin of the NYU Hospital for Joint Diseases|October 22, 2008
Update on the management of hyperuricemia and goutMichael H Pillinger, Robert T Keenan
Drugs of Today (Barcelona, Spain : 1998)|June 6, 2009
Febuxostat: a new agent for lowering serum urateRobert T Keenan, Michael H Pillinger
Current Rheumatology Reports|January 12, 2013
Genetics of hyperuricemia and gout: implications for the present and futureRonald L George, Robert T Keenan
Pageof 5